<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:  Early Diagnosis of the COVID-19 Cytokine Storm via Point-of-Care Antibody Profiling</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>12/15/2020</AwardEffectiveDate>
<AwardExpirationDate>11/30/2021</AwardExpirationDate>
<AwardTotalIntnAmount>256000.00</AwardTotalIntnAmount>
<AwardAmount>256000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Henry Ahn</SignBlockName>
<PO_EMAI>hahn@nsf.gov</PO_EMAI>
<PO_PHON>7032927069</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to predict a patient’s risk for developing an adverse and often lethal response to certain viral infections, such as COVID-19. This project proposes a fast and accurate test for the severity of COVID-19 infection.  The proposed assay has the potential to enable early intervention and save lives. It can potentially be used for many other infections and public health hazards beyond COVID-19.&lt;br/&gt;&lt;br/&gt;This Small Business Innovation Research (SBIR) Phase I project will produce a new technology capable of diagnosing immune response dysregulation to any infectious disease (e.g., SARS-CoV-2, dengue, influenza, hepatitis C, etc.) that progress through an antibody dependent enhancement (ADE) mechanism. While infection by the SARS-CoV-2 virus begins as a mild illness, some patients experience a sudden and rapid decline in health, precipitated by a massive release of pro-inflammatory cytokines, i.e., a “cytokine storm,” Cytokine storms cause hyperinflammation of the lungs, which leads to acute respiratory distress syndrome (ARDS), the leading cause of COVID-19 mortality. Unfortunately, there is presently no test capable of predicting this event. This project aims to fill this medical technology gap via the development of a highly multiplexed, rapid, sensitive, disposable immunoassay specific to COVID-19 infections to be deployed at scale. The effort will include designing, building, and optimizing a prototype immunoassay based on nanopore technology innovations and analytically validating the developed technology against industry standards.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>12/21/2020</MinAmdLetterDate>
<MaxAmdLetterDate>12/21/2020</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2036098</AwardID>
<Investigator>
<FirstName>Anna</FirstName>
<LastName>Schibel</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Anna Schibel</PI_FULL_NAME>
<EmailAddress>aschibel@electronicbio.com</EmailAddress>
<PI_PHON>8014287300</PI_PHON>
<NSF_ID>000654735</NSF_ID>
<StartDate>12/21/2020</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Electronic Bio Sciences</Name>
<CityName>San Diego</CityName>
<CountyName>SAN DIEGO</CountyName>
<ZipCode>921214206</ZipCode>
<PhoneNumber>8584121800</PhoneNumber>
<StreetAddress>5754 Pacific Ctr Blvd Ste 204</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>California</StateName>
<StateCode>CA</StateCode>
<CONGRESSDISTRICT>52</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>CA52</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>129852864</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>ELECTRONIC BIOSCIENCES, INC.</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM>129852864</ORG_PRNT_DUNS_NUM>
</Institution>
<Performance_Institution>
<Name><![CDATA[Electronic BioSciences, Inc.]]></Name>
<CityName>Salt Lake City</CityName>
<CountyName>SALT LAKE</CountyName>
<StateCode>UT</StateCode>
<ZipCode>841081244</ZipCode>
<StreetAddress><![CDATA[421 Wakara Way, Suite 328]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Utah</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>02</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>UT02</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>004E</Code>
<Text>BIOMEDICAL ENG AND DIAGNOSTICS</Text>
</ProgramReference>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<Appropriation>
<Code>0121</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2021~256000</FUND_OBLG>
</Award>
</rootTag>
